Recent developments of interest in cardiovascular medicine
In response to the FDA's updated safety notification for paclitaxel-coated or eluting peripheral artery devices, Philips and Medtronic said they remain confident in their devices. Philips said it will continue enrollment and follow-up of clinical trials with its Stellarex drug-coated balloon; Medtronic emphasized that none of the data has yet been able to demonstrate causality of the excess mortality risk.
Good cardiovascular health at age 50 is linked to lower dementia risk later on, a Whitehall II study analysis reported in BMJ.
Oops! Prescription fish oil icosapent ethyl (Vascepa) will get an FDA advisory committee meeting after all for a cardiovascular prevention indication, which will delay the potential approval date until the end of the year. (Endpoints News)
Plant-based food is good for the heart, affirmed an observational study "ripe" for puns, as Forbes sees it.
Mosaic has a long-form look at the realities of in-hospital cardiac arrest.
ICYMI: Sacubitril/valsartan (Entresto) failed to improve cardiovascular death and heart failure hospitalizations in heart failure with preserved ejection fraction in top-line results from the PARAGON-HF trial. Watch for the full data from the European Society of Cardiology meeting September 1. (Cardiovascular Business)
The American Heart Association weighed the various noninvasive means of assessing blood flow in critical limb ischemia in a new scientific statement. (Circulation)
FDA gave the Millipede CIS thrombectomy device breakthrough status for acute ischemic stroke. (Mass Device); CMS is about to make that status more lucrative. (RAPS.org)
A heart-on-a-chip system replicated adult human responses to drugs, researchers reported in the Journal of Toxicological Sciences.
Carbon nanotube fibers sewn into damaged heart tissue can restore its electrical function, according to a rodent and sheep study in Circulation: Arrhythmia and Electrophysiology.
Giving embryonic stem cell-derived epicardial and heart muscle cells together improved systolic function better than either alone, at least in rats. (Nature Biotechnology)
FDA cleared the way for a pivotal trial of the Nellix Chimney EndoVascular Aneurysm Sealing System (ChEVAS) for juxtarenal, pararenal, and suprarenal abdominal aortic aneurysms. (Vascular News)
A Swiss agency implemented a more sensitive test for nitrosamine impurities in sartan medicines to now detect down to 3 parts per billion for most. (in-PharmaTechnologist.com)
European regulators gave dapagliflozin (Forxiga) an indication in cardiovascular risk reduction for adults with type 2 diabetes. (Pharma Times)
Read the original article on Medpage Today: Vascepa Delay; Plant Food Puns; CLI Guide